CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social

The small drift in share count matters less as a headline and more as a signal that this remains a financing-driven story rather than a self-funding one. In a pre-commercial specialty pharma, every incremental share effectively lowers the probability-adjusted per-share value because upside is still anchored to binary de-risking, not recurring earnings. The fact that voting shares are essentially aligned with outstanding shares suggests governance is not the issue; dilution is.

The market mechanism here is convexity. If the next regulatory or BARDA-related milestone lands, the equity can re-rate sharply because the float is still relatively tight and expectations are low. But if timelines slip, the same structure works in reverse: thin liquidity plus ongoing share creep can force a lower equity value quickly as investors assume another capital raise. Immediate price impact should be limited, but the 1-3 month setup is sensitive to any financing signal or delay.

Contrarian take: investors may be treating this as a boilerplate disclosure, but for micro-cap biotech these notices are often the earliest visible clue that cash burn is continuing faster than de-risking. The real question over the next 6-18 months is whether non-dilutive funding arrives before the market has to underwrite a new equity round. If that answer is no, the stock is likely to remain a repeated-dilution story rather than a catalyst story.